Compare TG Therapeutics Inc (TGTX) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Virtu Financial Inc. Class A Common Stock — how do they compare? TG Therapeutics Inc trades at $53.27 (market cap $8.16B), while Virtu Financial Inc. Class A Common Stock trades at $57.47 (market cap $5.10B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.66% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 15 Days and Virtu Financial Inc. Class A Common Stock for 0 Days on average.
| TGTX | VIRT | |
|---|---|---|
Market Cap | $8.16B | $5.10B |
Volume | 1,735,121 | 871,626 |
Sector | Health | Financials |
52-Week High | $59.06 | $67.93 |
52-Week Low | $26.94 | $32.53 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $8.37B | $14.81B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $52.95, up 1.46% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results have missed expectations. Analyst sentiment remains largely positive, with an 84.62% buy rating and a consensus price target of $80.50, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook for TGTX is mixed, with robust revenue guidance and product momentum offset by earnings misses and negative cash flow. Key opportunities include BRIUMVI's expanding market share and potential buyout speculation, but risks involve ongoing legal scrutiny, competitive pressures, and the need to translate top-line growth into consistent bottom-line performance amid significant cash burn.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Virtu Financial Inc. Class A Common Stock
Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →
